Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
MIAMI, March 14, 2018 -- Veru Inc. (NASDAQ:VERU) today announced that that the company will present at the Oppenheimer 28th Annual Healthcare Conference at 1:35 p.m. ET on Wednesday, March 21, 2018 at the Westin New York Grand Central, in New York City.
A webcast of the presentation will be available at www.verupharma.com. The presentation will be archived and accessible on the web site for at least 90 days.
About Veru Inc.
Veru Inc. (Veru) is a biopharmaceutical company focused on urology and oncology. The company is currently developing drug product candidates: Tamsulosin DRS, slow release granules, and Tamsulosin XR capsules for lower urinary tract symptoms of benign prostatic hyperplasia (BPH) (NDA planned 2018), Solifenacin DRG, slow release granules, for overactive bladder (urge incontinence, urgency and frequency of urination) (NDA planned 2019), Tadalafil/finasteride combination capsule for restricted urination because of an enlarged prostate (NDA planned 2019), VERU-944 (cis-clomiphene citrate) for hot flashes in men associated with prostate cancer hormone treatment (planned Phase 2 in 2018), and VERU-111 a novel oral anti-tubulin cancer therapy targeting alpha & beta tubulin for a variety of malignancies, including metastatic prostate, breast, endometrial and ovarian cancers (planned Phase 1/2 in 2018).
To help support these clinical development programs, the company markets and sells the PREBOOST® medicated individual wipe, which is a male genital desensitizing drug product for the prevention of premature ejaculation which is being co-promoted with Timm Medical Technologies, Inc. and the FC2 Female Condom® (now available by prescription in the US including through the virtual doctor smartphone app “HeyDoctor” at www.fc2.us.com) in the United States and through The Female Health Company Division in the Global Public Health Sector. The Female Health Company Division markets to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. More information about Veru and its products can be found at www.verupharma.com, www.PREBOOST.com, www.fc2.us.com and www.fc2femalecondom.com. For corporate and investor-related information about the Company, please visit https://verupharma.com/investors.
| Contact: Kevin Gilbert | 786-322-2213 |
